Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

“The latest data from the IMPACT-TD Registry underscores the profound, multidimensional impact of tardive dyskinesia on individuals, extending far beyond any single demographic. Despite its widespread impact, we are still confronted with meaningful diagnostic gaps, leaving many patients undiagnosed and untreated,” said Verena Ramirez Campos, MD-MBA, Vice President U.S. Medical Affairs and Global Innovative Strategy at Teva. “We are committed to grasping the complete human experience of TD, and working to help close those gaps and bring forth innovations that make a meaningful difference in the day-to-day lives of people living with TD.”

The IMPACT-TD Registry, the largest TD study to date, is a 3-year, prospective, non-interventional, Phase 4 study examining how TD progresses over time and the impact it has on patients’ lives.^1-3 The study, which includes a broad representation of people affected by TD (age, sex, race/ethnicity, underlying conditions, movement severity and treatment status), evaluates 611 participants aged ≥18 years who, at enrollment, had either a score of ≥2 on at least one item of the Abnormal Involuntary Movement Scale (AIMS) and probable TD, or were receiving vesicular monoamine transporter 2 (VMAT2) inhibitor therapy for TD. The present analysis of the IMPACT-TD Registry evaluated 211 adults with TD who were not receiving VMAT2 inhibitor therapy at enrollment and had concomitant mood disorders, such as bipolar disorder (60%) or depression (54%), reflecting a diverse, real-world patient population. Multidimensional impact of TD was measured using the clinician-reported IMPACT-TD scale, while TD severity was assessed by AIMS.

The IMPACT-TD findings revealed:

• A majority of participants, regardless of age, reported a moderate to severe global impact from TD. This burden was particularly high for those aged 18-29 (85%) and 50-59 (87%, n=57), demonstrating that TD significantly affects daily life across the adult lifespan.
• The psychological impact of TD was most pronounced in adults aged <60. Over three-quarters (77%) of those aged 18-29 experienced moderate to severe psychological effects despite lower AIMS scores (6.4) on average compared to older adults aged 60-69 (8.4, n=56) and >69 (9.9, n=28).
• Despite the high impact, formal TD diagnosis rates were lowest among adults <40 years old. The rate was 23% for participants aged 18-29 and 35% for participants aged 30-39 (n=20), well below the peak of 57% seen in adults aged 40-49 (n=37) and 47% average in the 50+ age subgroups.
• A significant delay in diagnosis was also identified, with patients waiting an average of more than 3.5 years to be formally diagnosed after their involuntary movements were first recognized.
  
  

“Beyond the visible symptoms, tardive dyskinesia impacts every aspect of daily living, from personal independence to social interaction and emotional wellbeing,” said Richard Jackson, MD, an Assistant Clinical Adjunct Professor in the University of Michigan School of Medicine’s Department of Psychiatry and IMPACT-TD principal investigator. “What remains a critical unknown is how this debilitating condition uniquely impacts those already struggling with mood disorders, especially at different ages. The IMPACT-TD study is designed to bridge this crucial knowledge gap, giving us the insights we urgently need to offer targeted, meaningful support to every TD patient, no matter their background.”

Teva is committed to assisting in addressing these significant diagnostic gaps, which could improve the lives of those living with tardive dyskinesia.

About Tardive Dyskinesia (TD)
Tardive dyskinesia (TD) is a highly debilitating, chronic movement disorder that affects one in four people who take certain mental health treatments and is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact individuals.^4-6

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.